Exelixis Inc. Stock
Price
Target price
€32.50
€32.50
1.020%
0.33
1.020%
€39.00
20.08.25 / Tradegate
WKN: 936718 / Symbol: EXEL / Name: Exelixis / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Exelixis Inc. Stock
There is an upward development for Exelixis Inc. compared to yesterday, with an increase of €0.33 (1.020%).
With 44 Buy predictions and not a single Sell prediction Exelixis Inc. is an absolute favorite of our community.
With a target price of 38 € there is a slightly positive potential of 16.92% for Exelixis Inc. compared to the current price of 32.5 €.
So far the community has only identified positive things for Exelixis Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Exelixis Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Exelixis Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Exelixis Inc. | 1.020% | -1.186% | -15.077% | 36.440% | -0.429% | 68.779% | 71.685% |
| Ironwood Pharmaceuticals | -2.690% | 10.366% | 38.168% | -77.709% | -78.452% | -92.287% | -89.598% |
| Novocure Ltd | -1.160% | 1.884% | -26.543% | -35.696% | -65.264% | -87.178% | -84.734% |
| Iovance Biotherapeutics Inc. | -1.360% | 3.264% | 12.689% | -78.640% | -68.621% | -83.120% | -91.198% |
Comments
Exelixis, Inc. (NASDAQ: EXEL) had its price target lowered by analysts at HC Wainwright from $53.00 to $46.00. They now have a "buy" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its price target lowered by analysts at Truist Financial Corporation from $56.00 to $49.00. They now have a "buy" rating on the stock.
Show more
Ratings data for EXEL provided by MarketBeat
Exelixis, Inc. (NASDAQ: EXEL) had its "outperform" rating re-affirmed by analysts at William Blair.
Show more
Ratings data for EXEL provided by MarketBeat
News
Exelixis Stock: Mixed Signals After Earnings Beat
Biotech company Exelixis delivered notably mixed second-quarter 2025 results, creating divergent investor reactions. The California-based firm reported earnings per share of $0.75, significantly
Exelixis Q2 Revenue Falls 11 Percent
Exelixis (NASDAQ:EXEL), an oncology-focused biotech, reported results for Q2 2025 on July 28, 2025. For the period, the company delivered non-GAAP earnings per share (EPS) of $0.75 in Q2 FY2025
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
A decade ago, shares of Exelixis (NASDAQ: EXEL), a biotech company specializing in oncology, were trading for under $10 per share. Today, the drugmaker's shares are changing hands for about $45